VAXIL BIO LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.015 CAD | +50.00% |
|
0.00% | -40.00% |
| Sales 2021 | - | Sales 2022 | - | Capitalization | 2.74M 3.74M 218M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 0 | Net income 2022 | - 0 0 | EV / Sales 2021 | - |
| Net cash position 2021 | 2.24M 3.06M 179M | Net cash position 2022 | 1.51M 2.06M 120M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-10.4
x | P/E ratio 2022 |
-4.69
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 91.83% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +50.00% | ||
| 3 months | -40.00% | ||
| Current year | -40.00% |
1 week
0.01
0.02
1 month
0.010.02
Current year
0.010.03
1 year
0.010.04
3 years
0.010.16
5 years
0.000.77
10 years
0.000.77
| Managers | Title | Age | Since |
|---|---|---|---|
Gadi Levin
CEO | Chief Executive Officer | 52 | 29/02/16 |
Alan Rootenberg
DFI | Director of Finance/CFO | 72 | 30/07/23 |
Terry F. Plasse
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ari Kellen
BRD | Director/Board Member | - | 04/12/17 |
Gadi Levin
CEO | Chief Executive Officer | 52 | 29/02/16 |
Shawn Langer
BRD | Director/Board Member | - | 04/12/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.015 | +50.00% | 5,000 |
| 24/04/24 | 0.01 | 0.00% | 4,000 |
| 23/04/24 | 0.01 | -33.33% | 18,500 |
| 22/04/24 | 0.015 | 0.00% | 51,000 |
Delayed Quote Toronto S.E., April 26, 2024 at 08:10 pm
More quotes
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Companyâs most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
Calendar
26/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -40.00% | 1.5M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.26% | 22.15B | |
| -17.37% | 21.02B | |
| -8.79% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- VXL Stock
